Metraipolis › archive › dc_add077e7ec91

Baseline disease duration of chronic spontaneous urticaria participants in phase III clinical trials — Europe PMC PMID:41882772

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41882772
DOI
10.1186/s13223-[numero omesso]-0
License (as archived)
solo-consultazione
Archived
2026-10-08T05:38:35.636Z
SHA-256 of the archived text
2ec51a68e387c9f8048af65e1cfcf57608ed419a8890fa84dd32f5a6b0607026
Stable URL of this page
https://metraipolis.com/documento/dc_add077e7ec91

How to cite

Baseline disease duration of chronic spontaneous urticaria participants in phase III clinical trials — Europe PMC PMID:41882772 — Europe PMC (en), https://europepmc.org/article/MED/41882772 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_add077e7ec91 (Metraipolis archive dc_add077e7ec91, sha256 2ec51a68e387c9f8048af65e1cfcf57608ed419a8890fa84dd32f5a6b0607026)
BibTeX
@misc{dcadd077e7ec91,
  title = {Baseline disease duration of chronic spontaneous urticaria participants in phase III clinical trials — Europe PMC PMID:41882772},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41882772},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_add077e7ec91; sha256 2ec51a68e387c9f8048af65e1cfcf57608ed419a8890fa84dd32f5a6b0607026},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41882772. Agents can read the archived copy with the MCP tool read_document.